Where Will Tumor-Infiltrating Lymphocyte (TIL) Therapy Fit Into the Oncologic Landscape?

The first pretreated patient with HER2-altered non–small cell lung cancer was dosed with NVL-330, a novel HER2-selective inhibitor, in the HEROEX-1 trial.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

During a Case-Based Roundtable® event, John V. Heymach, MD, PhD, discusses the use of immunotherapy combinations based on patients PD-L1 expression in the first article of a 2-part series.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Jessica Paulus, ScD, discussed a study investigating real-world trends in lung cancer staging among community oncology practices.

During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed with participants how they select treatment for a patient with ALK+ non–small cell lung cancer and brain metastases in the first article of a 2-part series.